NCT02575807.

Trial name or title	A phase I/II open‐label safety and efficacy evaluation of CRS‐207 in combination with epacadostat in adults with platinum‐resistant ovarian, fallopian, or peritoneal cancer
Methods	Randomised phase I/II
Participants	126 participants with platinum‐resistant ovarian, fallopian, or peritoneal cancer
Interventions	Phase I cohort I: CRS‐207/epacadostat Phase I cohort II: CRS‐207 Phase 2 cohort I: CRS‐207, pembrolizumab Phase II cohort II: CRS‐207, pembrolizumab, epacadostat
Outcomes	DLT Adverse events Clinical response Survival
Starting date	October 2015
Contact information
Notes	Active not recruiting, February 2018